Concise Drug Review: Azacitidine and Decitabine-Reference-Cited by-同舟云学术

Concise Drug Review: Azacitidine and Decitabine

Published:2013-05-01 Issue:5 Volume:18 Page:619-624
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Derissen Ellen J.B.¹,Beijnen Jos H.¹²,Schellens Jan H.M.³²

Affiliation:

1. Department of Pharmacy & Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands;

2. Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands

3. Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;

Abstract

The introduction of the hypomethylating agents azacitidine and decitabine has been a major advancement in the treatment of patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia who are ineligible for more intensive treatments. This concise drug review summarizes the current state of treatment with azacitidine and decitabine.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2012-0465

Reference41 articles.

1. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome;Beran;Int J Hematol,2000

2. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

3. Optimizing hypomethylating agents in myelodysplastic syndromes;Itzykson;Curr Opin Hematol,2012

4. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study;Kantarjian;Cancer,2006

5. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group;Lübbert;J Clin Oncol,2011

Cited by 225 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic-modifying agents: the potential game changers in the treatment of hematologic malignancies;Critical Reviews in Oncology/Hematology;2024-09

2. Cardiotoxicity in Acute Myeloid Leukemia in Adults: A Scoping Study;Cancers;2024-07-06

3. Clinical Pharmacokinetics and Pharmacodynamics of Letermovir in Allogenic Hematopoietic Cell Transplantation;Clinical Pharmacokinetics;2024-07

4. De Novo Design of Inhibitors of DNA Methyltransferase 1: A Critical Comparison of Ligand- and Structure-Based Approaches;Biomolecules;2024-06-28

5. Insuficiencia renal aguda reversible tras administración de dosis única de azacitidina;Medicina Clínica;2024-06